Etiome key facts
as of Oct 2026- Developer of a biostaged medicine designed to map the progression of diseases.
- Etiome is valued at approximately $144.0M as of Oct 2026 (last reported valuation).
- It has raised $50.0M; the latest was Early Stage VC ($50.0M) in Apr 2025.
- Notable investors include Flagship Pioneering.
- Status: Privately Held (backing).
Etiome's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch Etiome: the Monday email on marks, rounds and moves
Etiome funding rounds
No funding rounds for Etiome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Etiome
1Etiome valuation
Etiome's last reported valuation was $144 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Etiome investors
1 investor is on record for Etiome, including Flagship Pioneering. By type, the record holds 1 venture capital firm.
About Etiome
Developer of a biostaged medicine designed to map the progression of diseases. The company's technology characterizes disease with increased resolution over time, and medicines are therapies tailored to specific stages of disease, enabling the healthcare industry to intervene at early disease stages and prevent further progression.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 24
- Website
- etiome.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.